BACKGROUND: Autopsy series have shown that some elderly people remain with normal cognitive function during life despite having high burdens of pathologic lesions associated with Alzheimer disease (AD) at death. Understanding why these individuals show no cognitive decline, despite high AD pathologic burdens, may be key to discovery of neuroprotective mechanisms. METHODS: A total of 36 subjects who on autopsy had Braak stage V or VI and moderate or frequent neuritic plaque scores based on Consortium to Establish a Registry for Alzheimer's Disease (CERAD) standards were included. Twelve had normal cognitive function and 24 a diagnosis of AD before death. Demographic characteristics, clinical and pathologic data, as well as antemortem brain volumes were compared between the groups. RESULTS: In multiple regression analysis, antemortem hippocampal and total brain volumes were significantly larger in the group with normal cognitive function after adjusting for gender, age at MRI, time from MRI to death, Braak stage, CERAD neuritic plaque score, and overall presence of vascular disease. CONCLUSION: Larger brain and hippocampal volumes were associated with preserved cognitive function during life despite a high burden of Alzheimer disease (AD) pathologic lesions at death. A better understanding of processes that lead to preservation of brain volume may provide important clues for the discovery of mechanisms that protect the elderly from AD.
BACKGROUND: Autopsy series have shown that some elderly people remain with normal cognitive function during life despite having high burdens of pathologic lesions associated with Alzheimer disease (AD) at death. Understanding why these individuals show no cognitive decline, despite high AD pathologic burdens, may be key to discovery of neuroprotective mechanisms. METHODS: A total of 36 subjects who on autopsy had Braak stage V or VI and moderate or frequent neuritic plaque scores based on Consortium to Establish a Registry for Alzheimer's Disease (CERAD) standards were included. Twelve had normal cognitive function and 24 a diagnosis of AD before death. Demographic characteristics, clinical and pathologic data, as well as antemortem brain volumes were compared between the groups. RESULTS: In multiple regression analysis, antemortem hippocampal and total brain volumes were significantly larger in the group with normal cognitive function after adjusting for gender, age at MRI, time from MRI to death, Braak stage, CERAD neuritic plaque score, and overall presence of vascular disease. CONCLUSION: Larger brain and hippocampal volumes were associated with preserved cognitive function during life despite a high burden of Alzheimer disease (AD) pathologic lesions at death. A better understanding of processes that lead to preservation of brain volume may provide important clues for the discovery of mechanisms that protect the elderly from AD.
Authors: E A Mueller; M M Moore; D C Kerr; G Sexton; R M Camicioli; D B Howieson; J F Quinn; J A Kaye Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2004 Oct-Dec Impact factor: 2.703
Authors: D A Bennett; J A Schneider; Z Arvanitakis; J F Kelly; N T Aggarwal; R C Shah; R S Wilson Journal: Neurology Date: 2006-06-27 Impact factor: 9.910
Authors: D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen Journal: J Neuropathol Exp Neurol Date: 2003-11 Impact factor: 3.685
Authors: Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen Journal: Brain Date: 2008-02-07 Impact factor: 13.501
Authors: Patricia L Kramer; Haiyan Xu; Randall L Woltjer; Shawn K Westaway; David Clark; Deniz Erten-Lyons; Jeffrey A Kaye; Kathleen A Welsh-Bohmer; Juan C Troncoso; William R Markesbery; Ronald C Petersen; R Scott Turner; Walter A Kukull; David A Bennett; Douglas Galasko; John C Morris; Jurg Ott Journal: Neurobiol Aging Date: 2010-05-07 Impact factor: 4.673
Authors: Karen S SantaCruz; Joshua A Sonnen; Maryam Kherad Pezhouh; Mark F Desrosiers; Peter T Nelson; Suzanne L Tyas Journal: J Neuropathol Exp Neurol Date: 2011-10 Impact factor: 3.685
Authors: D F Tate; E S Neeley; M C Norton; J T Tschanz; M J Miller; L Wolfson; C Hulette; C Leslie; K A Welsh-Bohmer; B Plassman; Erin D Bigler Journal: Brain Res Date: 2010-12-21 Impact factor: 3.252
Authors: N Maritza Dowling; Sarah Tomaszewski Farias; Bruce R Reed; Joshua A Sonnen; Milton E Strauss; Julie A Schneider; David A Bennett; Dan Mungas Journal: J Int Neuropsychol Soc Date: 2011-07 Impact factor: 2.892
Authors: Joshua A Sonnen; Karen Santa Cruz; Laura S Hemmy; Randall Woltjer; James B Leverenz; Kathleen S Montine; Clifford R Jack; Jeffrey Kaye; Kelvin Lim; Eric B Larson; Lon White; Thomas J Montine Journal: Arch Neurol Date: 2011-08
Authors: Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Steve Pedrini; Carlos Thomas; Hannah Brautigam; James Schmeidler; Lap Ho; Paul Fraser; David Westaway; Peter St George Hyslop; Ralph N Martins; Joseph D Buxbaum; Giulio M Pasinetti; Dara L Dickstein; Patrick R Hof; Michelle E Ehrlich; Sam Gandy Journal: Mol Neurodegener Date: 2009-10-21 Impact factor: 14.195